Benzinga (Thu, 9-May 2:59 PM ET)
Gold Moves Higher; Roblox Issues Weak Outlook
Benzinga (Thu, 9-May 2:30 PM ET)
CCLD, SKYT and SEED among mid-day movers
Seeking Alpha News (Thu, 9-May 1:12 PM ET)
Dow Jumps Over 150 Points; US Foods Posts Upbeat Earnings
Benzinga (Thu, 9-May 12:01 PM ET)
CytomX slides after early data for Amgen-partnered cancer drug
Seeking Alpha News (Thu, 9-May 11:33 AM ET)
Tivic Health, RAPT Therapeutics, Notable Labs among healthcare movers
Seeking Alpha News (Thu, 9-May 10:00 AM ET)
DTCK, NCI and SLNH among pre-market losers
Seeking Alpha News (Thu, 9-May 8:32 AM ET)
Cautious Hold on CytomX Therapeutics Pending Comprehensive CX-904 Drug Data
TipRanks (Thu, 9-May 6:43 AM ET)
Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)
TipRanks (Thu, 9-May 3:26 AM ET)
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Globe Newswire (Wed, 8-May 4:10 PM ET)
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Cytomx Therapeutics trades on the NASDAQ stock market under the symbol CTMX.
As of May 14, 2024, CTMX stock price climbed to $2.00 with 1,881,919 million shares trading.
CTMX has a beta of 1.91, meaning it tends to be more sensitive to market movements. CTMX has a correlation of 0.02 to the broad based SPY ETF.
CTMX has a market cap of $155.84 million. This is considered a Micro Cap stock.
Last quarter Cytomx Therapeutics reported $41 million in Revenue and $.17 earnings per share. This beat revenue expectation by $19 million and exceeded earnings estimates by $.23.
In the last 3 years, CTMX stock traded as high as $8.95 and as low as $1.04.
The top ETF exchange traded funds that CTMX belongs to (by Net Assets): VTI, VXF, FORH, IWC, ITOT.
CTMX stock has underperformed the market in the last year with a return of +12.4%, while SPY returned +28.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CTMX shares. However, CTMX has outperformed the market in the last 3 month and 2 week periods, returning +41.8% and +24.2%, while SPY returned +5.9% and +2.3%, respectively. This indicates CTMX has been having a stronger performance recently.
CTMX support price is $1.78 and resistance is $2.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTMX stock will trade within this expected range on the day.